PHARMACOGENETICS AND DRUG-METABOLISM - AN IRISH PERSPECTIVE

被引：3

作者：

HOLLAND, P ^{[1
]}

BARRY, M ^{[1
]}

FEELY, J ^{[1
]}

机构：

[1] ST JAMES HOSP,TRINITY COLL MED SCH,DEPT PHARMACOL & THERAPEUT,DUBLIN 8,IRELAND

来源：

IRISH JOURNAL OF MEDICAL SCIENCE | 1991年 / 160卷 / 02期

关键词：

D O I：

10.1007/BF02947648

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Genetic factors, particularly in relation to control of liver drug metabolism, are a major cause of variability in the response to drugs. In 145 Irish subjects 48% were fast acetylators of sulphadimidine in contrast to 80% in Chinese subjects. Eleven (7.6%) of our Irish population showed an improved ability to oxidise delrisoquine. The therapeutic implications of these findings are discussed.

引用

页码：54 / 56

页数：3

共 14 条

[1]

Feely, Practical Clinical Pharmacology: drug handling and response, Br. Med. J., 296, pp. 1046-50, (1988)

[2]

Clark D.W., Genetically determined variability in acetylalion and oxidation: therapeutic implications, Drugs, 29, pp. 342-75, (1985)

[3]

Price-Evans D., An improved and simplified method of detecting acetylator phenotype, J. Med. Genet., 6, pp. 405-7, (1969)

[4]

Lennard M.S., Silas J.H., Smith A.J., Tucker G.T., Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detectino, J. Chromatog, 133, pp. 161-166, (1977)

[5]

Mahgoub A., Idle J.R., Dring L.G., Lancaster R., Smith R.L., Polymorphic hydroxylation of debrisoquine in man, Lancet, 2, pp. 584-586, (1977)

[6]

Idle J.R., Oates N.S., Shah R.R., Smith R.L., Protecting poor metabolisers a group at high risk of adverse drug reactions, Lancet, 1, (1983)

[7]

Brosen K., Klysner R., Gram L.F., Otton S.V., Bech P., Bertillsson L., Steady state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism, European Journal of Clinical Pharmacology, 30, pp. 679-684, (1986)

[8]

Brosen K., Hagfelt L.F., Bertillsson T., Gram L., Extensive metabolisers of debrisoquine become poor metabolisers during quinidine treatment, Pharmac. Tox., 60, pp. 312-314, (1987)

[9]

Speirs J., Murray, Seddon C.E., Davies D.S., Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolisers of debrisoquine, Br. J. Clin. Pharmacol, 22, pp. 739-734, (1986)

[10]

Leeman T., Dayer P., Meyer U.A., Single dose quinidine treatment inhibits metoprolol oxidation in extensive metabolisers, European Journal of Clinical Pharmacology, 29, pp. 739-741, (1986)

← 1 2 →